Showing results (51-60 of 56) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Bioorganic & Medicinal Chemistry Letters|May 22, 2018
Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapyTianbao Lu, Carsten Schubert, Maxwell D Cummings, et al.Journal of Medicinal Chemistry|September 5, 2003
Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitorsGee-Hong Kuo, Catherine Prouty, Alan DeAngelis, et al.Bioorganic & Medicinal Chemistry Letters|May 30, 2008
Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinasesGuozhang Xu, Lily Lee Searle, Terry V Hughes, et al.Molecular Pharmacology|August 24, 2004
A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft modelsStuart Emanuel, Robert H Gruninger, Angel Fuentes-Pesquera, et al.Journal of Medicinal Chemistry|July 19, 2021
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal CancerZhuming Zhang, Avijit Ghosh, Peter J Connolly, et al.The Journal of Pharmacology and Experimental Therapeutics|December 11, 2019
Pharmacologic Characterization of JNJ-42226314, [1-(4-Fluorophenyl)indol-5-yl]-[3-[4-(thiazole-2-carbonyl)piperazin-1-yl]azetidin-1-yl]methanone, a Reversible, Selective, and Potent Monoacylglycerol Lipase InhibitorRyan M Wyatt, Ian Fraser, Natalie Welty, et al.Pageof 6